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Novel sensitive, specific and rapid pharmacogenomic 
test for the prediction of abacavir hypersensitivity 
reaction: HLA-B*57:01 detection by real-time PCR
Abacavir (ABC) is a nucleoside reverse transcrip-
tase inhibitor used as part of combination anti-
retroviral therapy in HIV-infected patients [1]. It 
has been extensively evaluated in clinical studies 
and is currently recommended as a preferred or 
an alternative nucleoside reverse transcriptase 
inhibitor in antiretroviral-naive patients accord-
ing to international HIV guidelines [101]. It is 
generally a very well-tolerated drug, even though 
an increased risk of myocardial infarction in 
patients exposed to ABC within the preceding 
6 months has been recently reported [2], but not 
confirmed by other studies [3]. The major rea-
son for early discontinuation of ABC remains 
the occurrence of an immunologically mediated 
hypersensitivity reaction (HSR) [4]. ABC-HSR 
has been observed in 5–8% of treated patients, 
appears within the first 6 weeks of therapy and 
requires an immediate and permanent dis-
continuation of the drug [5]. A strong associa-
tion between the ABC-HSR and MHC class I 
allele HLA-B*57:01 (locus position 6p21.3 and 
OMIM: 142830) has been observed in Caucasian 
HIV-infected patients [6,7]. Subsequently, skin 
patch testing demonstrated the presence of such 
an association across racial and geographic pop-
ulations [8,9]. Finally, a powered, double-blind, 
prospective, randomized study (Prospective 
Randomized Evaluation of DNA Screening in 
a Clinical Trial [PREDICT-1]) demonstrated 
the clinical utility of HLA-B*57:01 screening in 
reducing ABC-HSR in HIV-infected patients. 
HSR was clinically diagnosed in 93 patients 
from a total of 1650 patients, with a signifi-
cantly lower incidence (3.4%) in the prospec-
tive screening group than in the control group 
(7.8%; p < 0.001). Interestingly, HLA-B*57:01 
screening eliminated immunologically con-
firmed HSR, with a negative predictive value of 
100% [9]. Therefore, international HIV treat-
ment guidelines now recommend HLA-B*57:01 
typing before ABC administration, in order to 
reduce the incidence of ABC hypersensitiv-
ity [10,11,101]; while the screening is also part of 
the license of ABC-containing products.
Different technologies are available to detect 
individual HLA types that are routinely used 
for the characterization of tissue compatibility 
during organ transplantation, such as DNA 
sequence-based typing or the sequence-spe-
cific oligo nucleotide probe method with addi-
tional DNA sequencing for patients screened 
as positive with the probes. However, these 
approaches are time-consuming, expensive 
and not readily available [12]. An alternative 
method has been developed by Mallal’s group, 
based on the identification of the HLA-B*57:01 
allele by sequence-specific primer (SSP) by 
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semiquantitative PCR [12]. This methodology 
has been validated, and it has been widely dif-
fused for the rapid screening of HLA-B*57:01-
positive patients [13]. The assay was recently 
improved by Giardina and collaborators, using 
the same primer sets in a PCR assay based on 
fluorescence detection of the amplified products 
through capillary electrophoresis [14]. However, 
considering that most of the standard semi-
quantitative PCR techniques have been replaced 
by real-time (Q)-PCR, in the present study we 
have developed and characterized an alterna-
tive screening test based on the SSP method 
but using Q-PCR to detect the amplification 
products. We report the detailed methodology 
of this technique and the results of its validation 
by comparison with a reference method. 
Materials & methods
n DNA samples
A first group of 28 blood samples was provided 
by the Institute of Clinical Infectious Diseases, 
Catholic University Medical School of Rome 
(Italy) and the Department of Infectious 
Diseases, University of Sassari (Italy). These 
patients were originally recruited and thus 
geno typed as described below in the EPI109367 
clinical trial funded by GlaxoSmithKline (GSK; 
Brentford, UK) [15]. They were readmitted at 
the outpatient clinics (after institutional review 
board approval of an amended research protocol 
for HLA-B genotyping with a different method), 
whole blood samples were collected in EDTA-
treated tubes and used in the present study. 
These samples were initially used to optimize 
the experimental conditions, as detailed below. 
Subsequently, a panel of 80 additional DNA 
samples genotyped in the same clinical trial of 
the previous 28 were directly provided by GSK 
(Verona, Italy). These samples came from a 
multiethnic population and were genotyped by 
low-resolution sequence-specific oligonucleotide 
PCR, followed by high-resolution sequence-
specific oligonucleotide PCR carried out on 
the HLA-B*57 positive samples (Laboratory 
of Tissue Genotyping, Immunohematology 
and Transfusion Medicine Service, Fondazione 
IRCCSS, Centro San Raffaele del Monte Tabor, 
Milan, Italy). This method was validated during 
the EPI109367 clinical trial, comparing results 
from 776 blood samples analyzed with this 
method with results obtained by LabCorp (NC, 
USA) on buccal swabs collected from the same 
subjects by sequence-specific oligonucleotide 
probe PCR [15]. The latter method was validated 
during the PREDICT-1 clinical trial on 1956 
samples [9], by comparison with the gold stand-
ard technique based on DNA sequencing. This 
panel of samples was enriched in HLA-B*57:01-
positive samples (46.3%); moreover, six alleles 
belonging to the B*57 family were deliberately 
included. These alleles are discriminated on the 
basis of two mismatches in the exon-3-specific 
PCR primers, thus they were considered ‘diffi-
cult’ to detect in comparison to other alleles dis-
criminated on the basis of >2 mismatches. The 
exact number of positive samples, the number 
of ‘difficult’ alleles, together with the correct 
genotype of the samples included in the panel 
analyzed by our laboratory, were disclosed at the 
end of our ana lysis. These data are summarized 
in Table 1.
n Total DNA extraction.
Total DNA was prepared from whole blood 
samples, using the QIAamp® DNA Blood mini 
kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. Briefly, whole blood 
was collected in EDTA-treated tubes and stored 
at -20°C until the day of the extraction. Aliquots 
of 200 µl for each whole blood sample were used, 
and total DNA was eluted in 200 µl elution buf-
fer (10 mM Tris HCl; 0.5 mM EDTA; pH 9.0; 
provided by the kit). DNA concentration was 
measured using the Quant-iT™ PicoGreen® 
DNA Assay Kit (Invitrogen Corporation, 
Paisley, Scotland). A standard curve in the 
range of 0–10 ng was run in each assay using 
Lambda DNA standards, provided by the kit. 
Consistently, with data reported in the kit hand-
book, final DNA yield was approximately 5 µg 
per sample.
n HLA-B-specific amplification by PCR
HLA-B-specif ic amplif ication between the 
first and the third intron was carried out by 
PCR, using the following validated primers: 
5BIn1–57 forward primer (forward: 5´-GGG 
AGG AGC GAG GGG ACC G/CCA C-3´; 
intron 1: 36–57) and 3BIn3–37 reverse primer 
(reverse: 5´ -GGA GGC CAT CCC CGG CGA 
CCT AT-3 ;´ intron 3: 37–59), yielding a 922 bp 
product [16]. The PCR reaction contained 50 
ng total DNA, 1X PCR buffer, 300 nM of 
each primer, 1.25 U AccuPrime™ PfX DNA 
Polymerase (Invitrogen Corporation) in 50 µl 
final volume. After initial denaturation (10 
min at 95°C), a total of 35 PCR cycles were 
conducted, using the following two-step PCR 
conditions: denaturation at 95°C for 20 s and 
annealing/extension at 68°C for 1 min, in a 
MasterCycler ep thermo cycler® (Eppendorf, 
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Hamburg, Germany). The amplicons were sep-
arated by electrophoresis through 1.5% agarose 
gels containing 0.1 µg/ml ethidium bromide. 
This step allowed us to verify the efficiency of 
DNA amplification, in order to avoid the pro-
cessing of incorrect preamplified samples, thus 
reducing the incidence of false-negative results. 
n HLA-B*57:01 typing by SSPs Q-PCR
The Immunogenetics project (IMGT)/HLA 
database was used to align the HLA-B*57:01 
DNA sequence to other known HLA-B allele 
sequences [17]. The highest variability was found 
in the exon 2 and exon 3 sequences, which are 
regions that encode the peptide-binding domains 
of the MHC class I molecules. In this database, 
we initially found three different sequences rela-
tive to the HLA-B*57:01 allele, named progres-
sively as 57:01:01, 01:02 and 01:03, which dif-
fered for one mismatch on exon 3, as indicated 
in Figure 1 (red circles). These two SNPs were not 
included in the product of amplification when 
SSPs (black rectangles, Figure 1) were designed, 
so that all three HLA-B*57:01 alleles could be 
detected. By 15 October 2010 (the last released 
update), seven additional sequences had been 
stored in the IMGT/HLA database [17]. The 
HLA-B*57:01:04 allele, which differs by an A to 
G mutation at position 648 (AJ458991 sequence, 
NCBI GenBank database), is located within the 
PCR product amplified by exon-2-specific PCR 
(Figure 1a). This mutation does not interfere with 
the alignment of the primers, but may cause a 
small change in the melting temperature (Tm) 
of the amplification product. Nevertheless, the 
allele HLA-B*57:01:04 will be detected by 
amplifications in the two Q-PCRs. The point 
mutations found in the exon 2 sequences of the 
newly identified HLA-B*57:01:08 and 01:09 are 
not included in the amplified Q-PCR product, 
while the other newly identified sequences are 
identical in the exon 2 region (Figure 1a). The 
HLA-B*57:01:05–09 point mutations identified 
on the exon 3 region (Figure 1b) are not included 
in the product amplified by the exon-3-specific 
Q-PCR. Finally, the point mutation found in the 
exon 3 sequence of the HLA-B*57:01:10 allele is 
within the amplified Q-PCR product, and it is a 
C to G substitution, which does not change the 
Tm of the amplicon (Figure 1b). Taking all these 
observations together we can conclude that the 
additional HLA-B*57:01 alleles will be detected 
by our assay.
In order to encompass the highest variable 
regions of the HLA-B DNA sequence, two sets 
of primers were designed. The first set consisted 
of forward primer 345F (5 -´GTC TCA CAT 
CAT CCA GGT GAT GT-3´) and reverse 
primer 419R (5´ -GAC TGG TCA TGC CCG 
CGG AG-3´), allowing for the amplification of 
a 75 bp amplicon, corresponding to nucleo tides 
1020–1094 on exon 3 of the AJ458991 sequence, 
NCBI GenBank database (Figure 2a). This prod-
uct is similar but not identical to that previously 
described by Mallal and collaborators [12]. The 
second set of primers consists of forward primer 
193F (5 -´GCG AGT CCG AGG ATG GCG 
CC-3´) and reverse primer 319R (5´ -GGA GCG 
CGA TCC GCA GGT TCT-3´), which yield a 
127 bp product, corresponding to nucleotides 
622–748 on exon 2 of the AJ458991 sequence 
(NCBI GenBank database, Figure 2b). In Figure 2, 
the sequence of the HLA-B*57:01:01 is aligned to 
the official reference sequence HLA-B*07:02:01, 
Table 1. Allele distribution in the 
HLA-B*57:01-enriched panel of 
80 single-blind analyzed samples.
HLA-B status Replicates (n)
*07 6
*08 5
*13 2
*14 5
*15 5
*18 10
*27 4
*35 15
*38 9
*39 3
*40 4
*44 10
*47 1
*48 1
*49 3
*51 11
*53 2
*56 2
*57:01 37
*57:02 1
*57:03 5
*58 9
HLA-B typing was carried out by low-resolution 
sequence-specific oligonucleotide PCR, followed by 
high-resolution sequence-specific oligonucleotide PCR 
carried out on the HLA-B*57-positive samples (Laboratory 
of Tissue Genotyping, Immunohematology and 
Transfusion Medicine Service, Fondazione IRCCSS, Centro 
San Raffaele del Monte Tabor, Milan, Italy), a technique 
validated during the GlaxoSmithKline-funded EPI109367 
clinical trial [15]. Nine alleles were not univocally 
genotyped and were thus not included in this table. 
Among these, one allele was reported as HLA-B*57:01 
positive, even though data were also compatible with the 
HLA-B*57:14 genotype. Most patients were heterozygous, 
while one patient was homozygous for HLA-B*57:01, one 
for HLA-B*18 and one for HLA-B*38.
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corresponding to the AJ292075 sequence (NCBI 
GenBank database). 
HLA-B preamplified DNA was used for HLA-
B*57:01 allele detection by Q-PCR, performed 
with the two set of primers described above. 
Q-PCR conditions were set using two positive 
controls (data not shown). Q-PCR reactions 
were carried out in a 20 µl reaction volume, using 
163 nM of each primer and the Brilliant SYBR® 
Green Q-PCR Master Mix 2X (Stratagene, 
CA, USA) in a MX3000P Q-PCR machine 
(Stratagene). Reaction efficiency of approxi-
mately 98% was found in the dilution range of 
1:100 and 1:5000 using HLA-B preamplified 
DNA, while a significantly lower efficiency was 
detected when crude DNA was directly used as 
template in the Q-PCRs (data not shown). Thus 
HLA-B preamplified DNA diluted 1:1000 was 
chosen for subsequent assessments. 
The first group of 28 blood samples were 
analyzed in a single-blind fashion using the two 
Q-PCRs described above, with the following 
cycling conditions: 30 cycles of denaturation at 
95°C for 20 s; annealing at 64°C for the exon-3-
specific primers and 65°C for the exon-2-specific 
primers for 30 s; and extension at 72°C for 30 s. 
Data were analyzed using the amplification-based 
threshold and the adaptative baseline algorithms 
provided by the software ana lysis system of the 
MX3000P Q-PCR machine. The first algorithm 
automatically sets the threshold fluorescence for 
each dye, based on the amplification properties 
of each reaction; while the adaptative baseline 
algorithm calculates the best baseline for each 
amplification plot, thereby providing the most 
accurate fluorescence take-off point of reaction 
per sample, named threshold cycle (Ct). Using 
the automated algorithm to calculate the Ct val-
ues and detect amplifications by Q-PCRs, we 
identified four positive and 24 negative samples 
(Table 2), in complete concordance with results of 
the previous genotyping. Data obtained with this 
first set of samples were used to further standard-
ize Q-PCR conditions as follows: 20 cycles for 
the exon-3-specific Q-PCR, taking Ct values <15 
to determine positive amplifications; 15 cycles for 
the exon-2-specific Q-PCR, taking Ct values <14 
as positive amplifications (as described in detail 
in the ‘Results’ section). Using these Q-PCR 
parameters, we carried out a single-blind ana-
lysis of a panel of 80 additional DNA samples, 
directly provided by GSK.
n Data ana lysis
Results obtained with the analytical method 
for HLA-B*57:01 screening generated in our 
laboratory were compared with results obtained 
using a previously validated method. The 
k-statistic measure of inter-rater agreement for 
two unique raters and two ratings was calcu-
lated, according to the method described by 
Figure 1. DNA sequences relative to HLA-B*57:01. DNA sequences relative to 
the (A) exon 2 and (B) exon 3 regions of HLA-B*57:01 are aligned. When the 
sequence-specific primer (black rectangles) were designed in October 2007, the 
first three DNA sequences were found in the Immunogenetics project (IMGT)/HLA 
database [17]. These sequences differ for one mismatch (red circles), that was not 
included in the DNA region amplified by sequence-specific primer sets. However, at 
present, seven additional sequences are stored in the database. Pink rectangles 
refer to the sequences amplified between each primer set.
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Cohen [18]. k is a general measure of agreement 
for categorical data and it is computed using the 
following equation: 
Pr
Pr Pr
K
e
a e
1
=
-
-
^
^ ^
h
h h
where Pr(a) is the relative observed agreement 
among raters, and Pr(e) is the hypothetical prob-
ability of chance agreement. k can vary between 
-1 (complete disagreement) to +1 (complete 
agreement). Results were analyzed by Stata 10.1 
(Stata Statistical Software 10.1, StataCorp LP, 
TX, USA). 
Results
n Analysis of the first 28 samples
DNA samples from 28 individuals were analyzed 
in a single-blind fashion using a HLA-B-specific 
amplification followed by two sequence-specific 
Q-PCRs. Using the automatic algorithms pro-
vided by the Q-PCR software (see ‘Materials & 
methods’ section), four positive samples were 
identified, that is amplification in both Q-PCRs 
(Table 2). However, the Q-PCR designed for the 
exon 2 allowed for the identification of five posi-
tive samples (average Ct = 11.7) (Table 2). This 
primer set does not differentiate some alleles 
of the HLA-B*57 group, thus suggesting that 
the genotype of the additional positive sample 
belongs to the B*57 group. At present the HLA-
B*57 group includes 37 different alleles, identified 
progressively with two numbers, from B*57:01 
to B*57:37. Moreover, with the exon-2-specific 
Q-PCR we identified five additional samples with 
an average Ct value of approximately 14.9, three 
of which had similar Tm to the ones reported 
in Table 2. However, these higher Ct values are 
not compatible with possible differences in the 
amount of initial DNA template owing to the 
homo- or hetero-zygous status, which can only 
account for no more than ± 1 cycle difference 
(one cycle = double amount of DNA), thus they 
were considered nonspecific amplifications. For 
the same reason, all the amplifications detected 
in both Q-PCRs with Ct values higher than 
20 cycles were considered nonspecific. 
n Standardization of Q-PCR cycling 
conditions & data ana lysis
Results from the ana lysis of the first 28 samples 
were compared with the previous genotyping, 
and demonstrated a complete concordance; thus, 
they were used to standardize the Q-PCR profile 
setting and the ana lysis parameters in order to 
better compare data from different Q-PCR runs. 
Only the first 20 cycles were taken into account 
for a second ana lysis, which was carried out 
using a higher fluorescence threshold, manually 
adjusted to a fixed value arbitrarily chosen in the 
exponential phase of the amplification plot, which 
was equal to 0.05 for the exon 3 Q-PCR. This 
value was equal to 0.15 for the exon 2 Q-PCR. 
Moreover, the background correction was carried 
out using fluorescence values from cycle 3 to 10. 
Data from 21 samples analyzed with these param-
eters are shown in Figure 3. Briefly, the Ct values 
Table 2. Positive results from the first set of 28 patients who were 
analyzed in a single-blind fashion.
Sample 
number
Threshold Average Ct ± SEM 
(n = 3)
Average Tm ± SEM 
(n = 3)
Q-PCR exon 3
1 0.024 13.4 ± 0.1 85.45 ± 0.023 
2 0.024 13.5 ± 0.3 85.51 ± 0.020
3 0.020 10.6 ± 0.3 85.97 ± 0.001
4 0.020 10.9 ± 0.1 85.90 ± 0.183
Q-PCR exon 2
1 0.053 11.9 ± 0.1 85.90 ± 0.202
2 0.053 12.4 ± 0.1 86.30 ± 0.001
3 0.136 11.5 ± 0.04 86.47 ± 0.001
4 0.136 11.6 ± 0.1 86.08 ± 0.001
5 0.136 10.9 ± 0.1 85.95 ± 0.001
Samples were analyzed in two different PCR runs carried out per set of primers, as shown by 
differences in the threshold value. The latter was set by automatic algorithms provided by the Q-PCR 
software ana lysis system. Data, average Ct (each sample measured in triplicate) and average Tm 
values, relative to positive amplifications are reported. 
Ct: Threshold cycle; Q-PCR: Real-time PCR; SEM: Standard error of the mean;  
Tm: Melting temperature. 
75 bp product75-bp product
127 -p product127-bp product
Figure 2. HLA-B*57:01 alignment with the official reference sequence 
B*07:02:01. HLA-B*57:01 is aligned with the official reference sequence. The 
location of the sequence-specific primers within (A) exon 2 and (B) exon 3 is 
indicated (rectangles), and was selected in order to include the variable regions of 
the HLA-B DNA sequence to discriminate the allele of interest (B*57:01) and 
exclude other B alleles. 
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for the positive samples were as expected; higher 
than those reported in Table 2. In fact, the average 
Ct value of the positive samples measured in the 
exon 3 Q-PCR was 13.4 ± 0.7 (mean ± standard 
error of the mean [SEM], n = 4) with three cycle 
differences between the lower, and the highest Ct 
value; and a value of 12.8 ± 0.05 (mean ± SEM, 
n = 4) with two cycle differences between the 
lowest and the highest sample detected in positive 
assays using the exon 2 Q-PCR. 
Taking these data into account, subsequent 
Q-PCRs were run and analyzed as follows:
 Exon-3-specific Q-PCR: 20 cycles, cycle 3–10 
fluorescence values for background correction, 
fluorescence threshold of 0.05, and cut-off Ct 
value <15 to determine positive amplifications. 
The cut-off value was calculated considering the 
average Ct calculated for the positive samples 
(13.4) ± 1.5 cycle, since three cycle differences 
were measured among the lowest and the 
 highest positive sample.
 Exon-2-specific Q-PCR: 15 cycles, cycle 3–7 
fluorescence values for background correction, 
fluorescence threshold of 0.15, and cut-off Ct 
value <14 to determine positive amplifications. 
The cut-off value was calculated considering 
the average Ct calculated for the positive sam-
ples (12.8) ± 1 cycle, since two cycle differ-
ences were measured among the lowest and 
the highest positive sample. However, this 
Q-PCR will be used to confirm positive results 
obtained with the first PCR, and to exclude 
the presence of the 55:14, 57:16, 57:34 and 
58:14 alleles, which would be detected as 
positive with the exon-3-specific Q-PCR but 
negative with the exon-2-specific Q-PCR. 
Figure 3. Identification of HLA-B*57:01 by real-time PCR. (A & B) Exon-3- and (C & D) exon-2-specific real-time (Q)-PCR were run 
for 30 cycles on 21 samples; data were analyzed using fluorescence values detected within cycles 3–10 as background and a fixed 
threshold level. The first 20 cycles were considered for data ana lysis. In the exon-3-specific Q-PCR, two positive samples were detected 
with an average threshold cycle (Ct) of 12.2 (A) and a melting temperature (Tm) of 85.90 (B). In the exon-2-specific Q-PCR, three 
positive samples were detected with an average threshold cycle (Ct) of 11.8 (C) and a Tm of 86.17 (D). Five other samples had an 
average Ct value of 15, which was considered not compatible with possible variation in the initial quantity of DNA template owing to the 
homo- or hetero-zygous status. The latter would explain a difference of one cycle in the Ct value (one cycle = double DNA quantity).
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In order to assess the error rate owing to pos-
sible changes in the PCR efficiency, one posi-
tive sample was measured in triplicate in eight 
different PCR runs. The average Ct value was 
12.7 ± 0.3 (mean ± SEM, n = 8) for the exon-3-
specific PCR, and 11.9 ± 0.4 (mean ± SEM, n = 8) 
for the exon 2 PCR. Ct values measured in each 
PCR run were found consistently below the cut-
off Ct value, indicating the high reproducibility 
of the results in different PCR runs.
With these settings, we have analyzed in a 
single-blind fashion 80 DNA samples provided 
directly by GSK and previously genotyped in the 
EPI109367 trial. We identified a total of 37 HLA-
B*57:01-positive samples by detecting positive 
amplifications in both Q-PCRs. In particular, 
in the exon-3-specific Q-PCR, we identified 37 
positive samples, with an average Ct value of 12.9 
± 0.1 (SEM), and an average Tm of the ampli-
fication product equal to 85.48 ± 0.03 (SEM). 
By contrast, in the exon 2 Q-PCR, 43 positive 
sample were identified, with an average Ct value 
of 12.8 ± 0.1 (SEM), and an average Tm equal 
to 86.3 ± 0.03 (SEM). In Figure 4, Q-PCR fluo-
rescence plots and Tm for the first ten samples 
analyzed with the parameters described above 
are shown as an example of a typical Q-PCR 
assay. All data were compared with previous 
g enotyping data and a 100% overlap was found. 
In conclusion, we analyzed, with a Q-PCR 
screening test, a total of 108 samples, and identi-
fied 41 samples as positive and considered 67 as 
negative. Complete agreement was found with 
a validated methodology, with k for concord-
ance = 1 (standard error = 0.0962; p < 0.0001). 
Discussion
In the present paper we have validated a rapid 
pharmacogenomic test for the screening of the 
HLA-B*57:01 allele using SSPs and Q-PCR. 
Since the HLA-B*57:01 sequence differs in 
59 point mutations from the official HLA-B 
reference sequence, namely HLA-B*07:02:01 
(Figure 2), multiple sets of primers needed to be 
used in order to detect the allele of interest. We 
designed two sets of SSPs (approximately 20 bp 
oligonucleotides) that aligned the HLA-B*57:01 
sequence in two different regions; one in exon 
3 and another in exon 2. In the presence of the 
HLA-B*57:01 allele, primers bind DNA and a 
specific product can be amplified by Q-PCR 
and detected by SYBR Green fluorescence. In 
2005, the group of Mallal described an allele-
specific PCR method for the detection of HLA-
B*57:01, based on the use of a panel of four 
SSPs; one forward and three reverse primers [12]. 
Amplification of the HLA-B*57:01-specific 
sequence was detected by standard semiquan-
titative PCR, a method presently used by sev-
eral laboratories [13] which has been recently 
improved [14]. Fluorescence-based detection by 
capillary electrophoresis increases the sensitivity 
of Mallal’s method, thus allowing the use of as 
low as 1 ng of DNA per sample. This allows the 
employment of a noninfective source of DNA, 
such as saliva and buccal swabs, the main advan-
tage of this method [14]. The semiquantitative 
PCR technique has been progressively replaced 
by Q-PCR, a more rapid and sensitive method 
for the direct monitoring of DNA amplification 
during PCR cycling. In a subsequent study, the 
same research group described a faster test car-
ried out in Q-PCR [19]. For this approach, they 
used only three of the four HLA-B*57:01 SSPs 
previously characterized [12], thus missing the 
opportunity to discriminate the HLA-B*57:06 
allele [19]. Briefly, the authors used together 
with the HLA-B*57:01-specific primers, a set 
of primers specific for the housekeeping gene, 
the HGH gene, that yielded a 439-bp product. 
The authors set up a multiplex Q-PCR to favor 
amplif ication of the HLA-B*57:01-specific 
product when the allele is present instead of the 
amplification of the HGH-specific amplicon. 
The assessment of the HLA-B*57:01 status 
was carried out by analyzing differences in the 
melting curves of the two different amplified 
products [19]. However, our preliminary data 
demonstrated a significantly lower Q-PCR effi-
ciency and sensitivity when both primer sets 
were used directly on crude DNA preparation 
(data not shown); therefore, HLA-B-specific 
amplification using already validated primers 
was introduced in our strategy [16]. To prevent 
the introduction of nonspecific mutations dur-
ing this amplification step, we used a high fidel-
ity DNA polymerase as described in detail in the 
‘Materials & methods’ section.
The allele-specific PCR method described by 
Mallal is based on the recognition of a high 
variable DNA sequence located on exon 3; this 
region has also been included in our strategy. 
The forward primer used in this Q-PCR is simi-
lar to the one described by Mallal et al., how-
ever the reverse primers are located upstream, 
thus leading to the amplification of a shorter 
product of 75 bp [12]. This shift allowed us 
to discriminate the following alleles: 57:02, 
57:03, 57:04, 57:05, 57:07, 57:09, 57:12 and 
the newly identified 57:17 allele, via one addi-
tional mismatch in comparison to the reverse 
primer used by Mallal’s group [12]. In fact, we 
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identified six samples as negative in the exon 3 
Q-PCR and positive in the exon 2 Q-PCR, 
and hypothesized that they were alleles of the 
B*57 group. These samples corresponded to one 
HLA-B*57:02 allele and five HLA-B*57:03 alle-
les included in the panel of known GSK sam-
ples. Based on these experimental data and the 
sequence ana lysis, we also expected to detect 
other alleles of the B*57 family indicated above 
as negative on exon-3-specific Q-PCR and posi-
tive in the exon-2-specific Q-PCR. The latter 
reaction allows for the amplification of a sec-
ond variable region within the exon 2 sequence, 
using a SSP set. 
Finally, the amplif ication of a product 
within the two Q-PCRs allows for the identi-
fication of HLA-B*57:01, including all of the 
ten sequences deposited for this allele, along 
with HLA-B*57:06, -57:08, -57:10 and -57:13 
alleles and the newly identified HLA-B*57:14, 
-57:15, -57:18–20, -57:22–27, -57:29–33 
and -57:35–37 which are absolutely identical 
in the regions examined. However, B*57:06 
and B*57:08 alleles have a 0% frequency in 
the Caucasian population [20], and thus do 
not represent a significant confounding fac-
tor. There is no information available regard-
ing the frequency of other alleles in different 
populations, thus suggesting that they may be 
very rare. Similar to our technique, the stand-
ard SSP-PCR method [12], widely used in other 
laboratories as a fast screening test as well as the 
newly described fluorescence method [14], does 
not discriminate these newly identified alleles, 
as well as the B*57:16 and B*57:34 alleles that 
are detected instead by our strategy using a mis-
match in the forward primer of the exon-2-spe-
cific Q-PCR. However, the need for a continu-
ous update of the primer sets based on newly 
identified DNA polymorphisms represents a 
limit of SSP-based techniques; thus, this work 
is an important update on the sequence studies 
Figure 4. Use of standardized real-time PCR conditions for detection of HLA-B*57:01. (A & B) Exon-3- and (C & D) exon-2-
specific real-time (Q)-PCR were run for 20 and 15 cycles, respectively, on the first ten GlaxoSmithKline samples (Figure 1); data were 
analyzed using fixed parameters for background correction and fluorescence threshold in order to compare different runs. In the 
exon-3-specific Q-PCR, six positive samples were detected with an average threshold cycle (Ct) of 12.6 (A) and a Tm of 85.47 (B). 
Similarly, in the exon-2-specific Q-PCR six positive samples were detected with an average Ct of 13.2 (C) and a Tm of 86.01 (D).
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Executive summary
  International HIV treatment guidelines recommend HLA-B*57:01 typing before abacavir administration, in order to reduce the incidence 
of abacavir hypersensitivity reaction.
  Technologies available to detect individual HLA types, such as DNA sequence-based typing or the sequence-specific oligonucleotide 
probe method with additional DNA sequencing for patients screened as positive with the probes, are time-consuming, expensive and 
not readily available.
  In 2005, Mallal’s group developed an quick method for HLA-B*57:01 screening, based on the use of a panel of 
sequence-specific primers and standard PCR technique. This assay has been recently improved by fluorescence-based detection via 
capillary electrophoresis.
Results
  Two sets of sequence-specific primers have been designed and a novel test, based on real-time PCR technique, has been developed and 
validated in the present study.
Conclusion
  This test is rapid, allowing for the processing of 30 samples in 24 h, is sensitive and specific, inexpensive in comparison to already 
available alternatives, and can be easily implemented into routine clinical practice.
  The main limitation of this approach, and in general with sequence-specific primer techniques, is represented by the continuous need 
for sequence updating owing to the highly polymorphic nature of the HLA-B gene.
  Since the seminal work of Mallal’s group, approximately 1000 new sequences have been identified for the HLA-B gene; thus, a useful 
update of sequence studies has been provided in the present paper.
reported in the abovementioned papers [12,14]. 
Another advantage of our technique is the pos-
sibility to discriminate additional alleles, such 
as HLA-B*55:14 and -58:14. 
In this regard, we should also report that 
the validated methodology used to compare 
our results provided, with respect to the few 
alleles analyzed, results compatible with differ-
ent geno typing studies (Table 1). Among these, 
the genotype of one HLA-B*57:01-positive 
sample was also compatable with the HLA-
B*57:14-specific sequence. These data sug-
gest that with respect to some B*57 alleles, 
the only technique able to detect differences 
is the DNA sequence-based typing, which still 
remains the gold standard technique. However, 
since the frequency of such alleles seems to be 
extremely low, they should not represent a criti-
cal c onfounding factor. 
Conclusion
In the present paper, we provided evidence to 
suggest the adoption of the test herein charac-
terized into clinical practice as a fast method 
to screen for HLA-B*57:01 status, particularly 
in those laboratories already involved in detec-
tion of viral load and virus genotyping. The 
test described may be considered as an alterna-
tive to Mallal’s test for those laboratories that 
can have access to the Q-PCR technique. In 
particular, with respect to the validated meth-
odology used to compare our method, the assay 
presented in this paper can allow the processing 
of 30 samples versus 10 samples in one single 
assay. The genotype results can be provided in 
24 h (30 patients) versus 48 h of the reference 
method (ten patients). The entire assay is run 
in approximately 6–8 h. 
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